Recordati Group
Clinical trials sponsored by Recordati Group, explained in plain language.
Pharmaceutical company focused on rare diseases and specialty treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cushing's drug osilodrostat under Long-Term safety review Results expected Jun 2027 (estimated)
- New hope for kids with Cushing's: drug trial launches Results expected Jul 2027 (estimated)
-
Cushing's drug osilodrostat under Long-Term safety review
Disease control OngoingThis study follows 206 patients with Cushing's syndrome who are taking osilodrostat (Isturisa) to see how safe and effective it is over time. Researchers will track side effects and how well the drug controls cortisol levels. No new treatment is given—just real-world monitoring.…
Sponsor: RECORDATI GROUP • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for Post-Surgery sugar crashes: pasireotide under study
Disease control OngoingThis phase 2 trial tests the drug pasireotide in 93 adults who experience severe low blood sugar after weight-loss surgery. Participants receive either the drug or a placebo for 12 weeks, then all can receive the drug for 36 more weeks. The goal is to see if pasireotide can stabi…
Phase 2 • Sponsor: RECORDATI GROUP • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New registry aims to unlock secrets of rare blood disorder
Knowledge-focused OngoingThis study is a registry that collects information from about 429 adults with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS), a rare condition where the immune system attacks red blood cells in cold temperatures. Researchers will track symptoms, treatments, compl…
Sponsor: RECORDATI GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC